Oyster Point Pharma has enrolled the first patient in a phase 2 clinical trial investigating the safety and efficacy of OC-01 nasal spray in patients with neurotrophic keratopathy, according to a press release.
The randomized, multicenter, double-masked, placebo-controlled OLYMPIA trial of OC-01 (varenicline) nasal spray is expected to enroll about 100 patients with Mackie’s classification stage 1 neurotrophic keratopathy across 18 U.S. sites. The primary endpoint is the percentage of patients who achieve complete resolution of corneal fluorescein staining at day 56.
“This is an